# Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

> **NCT00357656** · PHASE4 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 85 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Recombinant Protein-Free Factor VIII (rAHF-PFM)
- **DRUG:** Recombinant Protein-Free Factor VIII (rAHF-PFM)

## Key facts

- **NCT ID:** NCT00357656
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05-29
- **Primary completion:** 2015-10-01
- **Final completion:** 2015-12-09
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2021-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00357656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00357656, "Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00357656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*